FINWIRES · TerminalLIVE
FINWIRES

Bio-Rad Laboratories' Sales Growth Set to Recover in 2027, RBC Says

By

Bio-Rad Laboratories' (BIO) sales growth should recover in 2027 following idiosyncratic product headwinds, RBC Capital Markets analysts said in a Thursday note.

Analysts said that the company's new management will make efforts to structurally improve its margin profile.

RBC said that some of the challenges Bio-Rad faces are company-specific, noting, for instance, that demand for Bio-Rad's process chromatography products is negatively impacted this year by the US Center for Disease Control's revisions of the childhood and adolescent immunization schedule.

Analysts said that the company's near-term earnings before interest and taxes, or EBIT, margin growth target in the mid-teens, up from the 11% guidance for 2026, strongly signals meaningful restructuring ahead.

RBC resumed coverage on the stock with an outperform rating and a $320 price target.

Price: $248.61, Change: $+2.34, Percent Change: +0.95%

Related Articles

Wire

Aardvark Therapeutics' Investigational New Drug Application for ARD-101 Put on Clinical Hold by FDA

Aardvark Therapeutics (AARD) said late Thursday the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101 to treat hyperphagia associated with Prader-Willi Syndrome.The hold applies to all ongoing clinical studies under the IND, the company said, adding that it is in discussions with the FDA for resolution of the clinical hold and to fix a path forward for the drug candidate.The company also plans to unblind clinical data from the HERO and OLE trials to assess the totality of efficacy and safety data, according to the company.The company said it had $91.2 million in cash and cash equivalents as of March 31, adequate to fund operations into mid-2027.

$AARD
Wire

Sky Harbour Q1 Loss Narrows, Revenue Rises; Shares Fall After Hours

Sky Harbour Group (SKYH) reported a Q1 loss late Thursday of $0.16 per diluted share, narrowing from a loss of $0.19 a year earlier.Analysts polled by FactSet expected a loss of $0.13.Revenue in the three months ended March 31 rose to $8.73 million from $5.59 million a year earlier.Analysts surveyed by FactSet expected $9.8 million.Sky Harbour shares fell 4.9% in after-hours trading.

$SKYH
Wire

KinderCare Learning Q1 Adjusted Earnings Fall, Revenue Rises; Shares Drop After Hours

KinderCare Learning (KLC) reported Q1 adjusted earnings late Thursday of $0.04 per diluted share, down from $0.23 a year earlier.Analysts surveyed by FactSet expected a loss of $0.01.Revenue in the three months ended April 4 rose to $672.5 million from $668.2 million a year earlier.Analysts surveyed by FactSet expected $669.1 million.The company boosted full-year adjusted EPS guidance to $0.15 to $0.25 from the previous forecast of $0.10 to $0.20. It affirmed the revenue outlook of $2.7 billion to $2.75 billion.Analysts expect EPS of $0.15 on revenue of $2.71 billion.KinderCare shares fell 6.2% in after-hours trading.

$KLC